Title:
受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法
Document Type and Number:
Japanese Patent JP7312451
Kind Code:
B2
Abstract:
From gene expression analysis with a long-term recurrence-free group and a recurrence metastasis group of stomach cancer, CHRNB2 and NPTXR were identified as drug discovery targets. Tumor growth was successfully inhibited by an antibody medicine or a nucleic acid medicine targeting CHRNB2 or NPTXR. Furthermore, a polyclonal antibody and a monoclonal antibody linking to CHRNB2 or NPTXR are provided. Since these receptor molecules are novel molecular targets, treatment of cases which the existing therapeutic drugs have no effect on is made possible.
Inventors:
Mitsuro Kanda
Application Number:
JP2019567188A
Publication Date:
July 21, 2023
Filing Date:
January 25, 2019
Export Citation:
Assignee:
Tokai National University Organization
International Classes:
A61K39/395; A61K31/7105; A61K48/00; A61P35/00; C12N15/113; C12N15/115; C12Q1/6886; G01N33/15; G01N33/50; G01N33/574
Domestic Patent References:
| JP2003533229A | ||||
| JP2010536366A |
Other References:
STILL PC. et al.,Alkaloids from Microcos paniculata with Cytotoxic and Nicotinic Receptor Antagonistic Activities,JOURNAL OF NATURAL PRODUCTS,2013年,Vol.76,p.243-249
JONES IW. et al.,Presynaptic Localisation of the Nicotinic Acetylcholine Receptor β2 Subunit Immunoreactivity in Rat,THE JOURNAL OF COMPARATIVE NEUROLOGY,2001年,Vol.439,p.235-247
JONES IW. et al.,Presynaptic Localisation of the Nicotinic Acetylcholine Receptor β2 Subunit Immunoreactivity in Rat,THE JOURNAL OF COMPARATIVE NEUROLOGY,2001年,Vol.439,p.235-247
Attorney, Agent or Firm:
Seiji Matsumoto